Pilbara Exploration Update

Go back to Pilbara Exploration Update

Morgan Stanley Reiterates Equalweight Rating on Novo Nordisk (NOVOB:DC) (NVO)

June 23, 2025 1:35 PM UTC

Morgan Stanley analyst Thibault Boutherin reiterated an Equalweight rating and DKK550.00 price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO).

The analyst comments "H&H partnership termination (see press release here): Novo entered the arrangement with H&H before the 22 May (date of removal of sema from FDA shortage list) in order to facilitate the transition of patients on compounded semaglutide to Wegovy. Management reiterated that mass compounding and mass personalisation are against Novo's values and the direction they see for the market in the long term, and stated that Novo will not... More